Grifols (NASDAQ:GRFS) shares are trading higher on Thursday. The company announced it's working with the U.S. biomedical advanced research development authority and the FDA to collect plasma from COVID-19 patients.
The plan is to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can successfully be used to treat COVID-19 disease.
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.
Grifols is a Spanish multinational pharmaceutical and chemical manufacturer headquartered in Barcelona. The company is a producer of blood plasma-based products and supplies devices, instruments, and reagents for clinical testing laboratories.
Grifols ADR class B shares were trading up 9.34% at $19.43 on Thursday. The stock has a 52-week range between $25.73 and $13.40.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!